Skip to main content

Organ Health Publications

Renasight | Prospera Kidney | Prospera Lung | Prospera Heart

Renasight

  1. PKD/Sickle Cell Case Report | Open Access
    Stein Q, Herman K, Deyo J, et al. Dual diagnosis of autosomal dominant polycystic kidney disease and sickle cell disease in a teenage male. Pediatr Nephrol. (2023). 38(9):3189-3192. doi: 10.1007/s00467-023-05873-6
  2. Genetic counseling Perspectives | Open Access
    Stein Q, Westemeyer M, Darwish T, et al. Genetic Counseling in Kidney Disease: A Perspective. Kidney Medicine (2023). 5(7):100668. doi: 10.1016/j.xkme.2023.100668.
  3. CUBN Case Report | Open Access
    Shi V, Stein Q, Clark D, et al. Isolated benign persistent proteinuria with novel association of CUBN (cubilin) variants. 11(6):e7502. doi: 10.1002/ccr3.7502
  4. RenaCARE Primary Readout | Open Access (Published ahead of Print)
    Dahl N, Bloom MS, Chebib FT, et al. The Clinical Utility of Genetic Testing in the Diagnosis and Management of Adults With Chronic Kidney Disease. J Am Soc Nephrol ():10.1681/ASN.0000000000000249.
  5. Renasight 1000 | Open Access
    Bleyer AJ, Westemeyer M, Xie J, et al. Genetic Etiologies for Chronic Kidney Disease Revealed through Next-Generation Renal Gene Panel. Am J Nephrol. 2022. 53(4):297-306.
  6. Genetic Testing in Kidney Donors | Open Access
    Singh G, Gohh R, Clark D, et al. Vignette-Based Reflections to Inform Genetic Testing Policies in Living Kidney Donors. Genes. 2022;13(4).
  7. COL4A4 Case Report | Open Access
    Cocorpus J, Hager MM, Benchimol C, et al. COL4A4 variant recently identified: lessons learned in variant interpretation-a case report. BMC Nephrol. 2022;23(1):253.
  8. Alport Case Study | Open Access
    Tantisattamo E, Reddy UG, Ichii H, et al. Is It Time to Utilize Genetic Testing for Living Kidney Donor Evaluation? Nephron 2021. doi: 10.1159/000520150
  9. General Nephrology Survey | Open Access
    Mrug M, Bloom MS, Seto C, et al. Genetic Testing for Chronic Kidney Diseases: Clinical Utility and Barriers Perceived by Nephrologists. Kidney Medicine

    (2021) doi: https://doi.org/10.1016/j.xkme.2021.08.006.

  10. Renal PGT-M | Open Access
    Chaperon JL, Wemmer NM, McKanna TA, et al. Preimplantation Genetic Testing for Kidney Disease-Related Genes: A Laboratory’s Experience. Am J Nephrol 2021. doi: 10.1159/000518253

Prospera Kidney

  1. Trifecta Study: Subthreshold ABMR-like Activity | Open Access
    Halloran, et al. Distinct Molecular Processes Mediate Donor-derived Cell-free DNA Release From Kidney Transplants in Different Disease States. Transplantation. 2023
  2. Trifecta Study: Molecular Correlations with cfDNA | Open Access
    Halloran PF, Reeve J, Madill-Thomsen KS, et al. The Trifecta study: comparing plasma donor-derived cell-free DNA levels with the molecular phenotype of kidney transplant biopsies. J Am Soc Nephrol. 2022. 33(2):387-400.
  3. Clinical Experience of Prospera in Simultaneous Pancreas-kidney Recipients | Open Access
    Ventura-Aguiar P, Ramirez-Bajo MJ, Rovira J, et al. Donor-derived Cell-free DNA Shows High Sensitivity for the Diagnosis of Pancreas Graft Rejection in Simultaneous Pancreas-kidney. Transplantation. 2022;106(8):1690-1697.
  4. Case Study Series of Prospera use in COVID-19 patients | Open Access
    Reusing Jr JO, Yoo J, Desai A, et al. Association between total cell free DNA and SARS-CoV-2 in Kidney Transplant Patients: A Preliminary Study. Transplantation Proceedings. 2022; 54(6):1446-1454.
  5. Trifecta Study: Two Threshold Caller Validation | Open Access
    Halloran PF, Reeve J, Madill-Thomsen KS, et al. Combining Donor-derived Cell-free DNA Fraction and Quantity to Detect Kidney Transplant Rejection Using Molecular Diagnoses and Histology as Confirmation. Transplantation. 2022.
  6. Trifecta Study: ABMR and DSA | Open Access
    Halloran PF, Reeve J, Madill-Thomsen KS, et al. Antibody-mediated Rejection Without Detectable Donor-specific Antibody Releases Donor-derived Cell-free DNA: Results From the Trifecta Study. Transplantation. 2022.
  7. Prospera 1300 Clinical Experience | Open Access
    Qazi Y, Patel A, Fajardo M, et al. Incorporation of Donor-derived Cell-free DNA Into Clinical Practice for Renal Allograft Management. Transplant Proc. 2021. 10:S0041-1345(21)00710-7. doi: 10.1016/j.transproceed.2021.09.027.
  8. Single Center Head-to-head Experience of Two dd-cfDNA tests | Open Access
    Lum EL, Nieves-Borrero K, Homkrailas P, et al. Single center experience comparing two clinically available donor derived cell free DNA tests and review of literature. Transplantation Reports. 2021;6(3).
  9. Single Center Experience of Improved Sensitivity with Prospera Two Threshold Algorithm over Fraction-alone | Open Access
    Bunnapradist S, Homkrailas P, Ahmed E, et al. Using Both the Fraction and Quantity of Donor-Derived Cell-Free DNA to Detect Kidney Allograft Rejection. J Am Soc Nephrol 2021:32 (10) 2439-2441; DOI: 10.1681/ASN.2021050645
  10. Case study of Prospera use in COVID-19 patient | Open Access
    Bunnapradist S, Datta N, Schaenman J, et al. Extremely High Cell-free DNA Levels Observed in Renal Allograft Patient With SARS-CoV-2 Infection. Transplantation Direct. 2021;7(5)
  11. CPV-simulated Renal transplants | Open Access
    Peabody J, Billings P, Valdenor C, et al. Randomized clinical trial of a novel donor derived cfDNA test to detect rejection in CPV-simulated renal transplant patients. Int Urol Nephrol. 2020; 52(8):1593-1601.
  12. Letter to the Editor Response regarding Prospera Kidney Analytical Validation | Open Access
    Altug Y, Demko ZP, Ryan A. The Author's reply to the "Performance of Donor-derived Cell-free DNA Assays in Kidney Transplant Patients". Letter to the Editors - Transplantation. 2020;104(5):e135-137
  13. Survey of Nephrology Practices' Assessment of Renal Allografts | Open Access
    Peabody J, Billings P, Valdenor C, et al. Variation in assessing renal allograft rejection: a national assessment of nephrology practice. International Journal of Nephrology. Vol. 2019; Article ID 5303284, 6 pages.
  14. Analytical validation | Open Access
    Altuğ Y, Liang N, Ram R, et al. Analytical Validation of a Single-Nucleotide Polymorphism-Based Donor-Derived Cell-Free DNA Assay for Detecting Rejection in Kidney Transplant Patients. Transplantation. 2019;103(12):2657-2665.
  15. Clinical validation | Open Access
    Sigdel TK, Acosta Archila F, Constantin T, et al. Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR. J Clin Med. 2019;8(1):19.

Prospera Lung

  1. ALAD-Spectrum | Open Access
    Girgis R, Lawson C, Bhorade S, et al. Real-World Clinical Experience Implementing Donor-Derived-Cell Free DNA for Detection of Acute Lung Allograft Dysfunction after Lung Transplantation. Mar Pulmonology and Respiratory Medicine (2023) 6:3. DOI:10.1027/margy.2023.0156.
  2. Lung Validation | Open Access
    Rosenheck JP, Ross DJ, Botros, M, et al. Clinical Validation of a Plasma Donor-derived Cell-free DNA Assay to Detect Allograft Rejection and Injury in Lung Transplant. Transplantation Direct. 2022;8(4).
  3. Game Changer Review | Open Access
    Rosenheck JP, Keller BC, Fehringer G, et al. Why Cell-Free DNA Can Be a “Game Changer” for Lung Allograft Monitoring for Rejection and Infection. Curr Pulmonol Rep. 2022.
  4. dd-cfDNA in CLAD | Open Access
    Levine DJ, Demko ZP, and Ross DJ. Variability in plasma donor-derived cell-free DNA levels with CLAD more than 5-years after Lung Transplantation: Pilot data. Transplantation Reports. 2022;7(3).

Prospera Heart

  1. Heart Validation | Open Access
    Kim PJ, Olymbios M, Siu A, et al. A novel donor-derived cell-free DNA assay for the detection of acute rejection in heart transplantation. J Heart Lung Transplant. 2022.